Is It Too Late to Buy Pfizer Stock?
Pfizer (NYSE: PFE) has become an expert at firsts. The pharmaceutical giant became the first to launch a coronavirus vaccine last year. Since then, it's scored a bunch more: bringing a COVID-19 booster to market, winning authorization for its vaccine in teens, and most recently, winning vaccine authorization for kids.
Massive revenue has followed. In fact, the company recently increased its forecast for coronavirus vaccine revenue this year to $36 billion. And Pfizer also lifted its forecast for total revenue to at least $81 billion because its other blockbusters also are growing.
At the same time, the stock has gained about 18% this year. So now the big question is: Is it too late to buy shares of Pfizer?
Source Fool.com
